Who founded Immuneering?

Immuneering was founded by Benjamin J. Zeskind.

How much funding has Immuneering raised?

Immuneering has disclosed $82.2M raised across 3 rounds.

Where is Immuneering headquartered?

Immuneering is headquartered in Cambridge, US.

Immuneering

NASDAQ: IMRX

Cambridge, US · Delaware corporation

immuneering.com ↗

Immuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.

BiotechHealthtech

Founders & leadership

Benjamin J. ZeskindFounder

Joseph KekstNamed on SEC filing

Board

Peter FeinbergBoard director

Laurie B. KeatingBoard director

Robert CarpenterBoard director

Thomas J. SchallBoard director

Diana F. HausmanBoard director

Reported raises · per SEC filings

Form D private placements

$82.2M disclosed across 3 rounds · 2020–2025

▶$25MraisedSep 2025 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Benjamin J. ZeskindExecutive Officer, Director
Laurie B. KeatingDirector
Robert CarpenterDirector
Thomas J. SchallDirector
Diana F. HausmanDirector
Peter FeinbergDirector

Offering amount: $25M
Amount sold: $25M
First sale: Aug 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$37.2MraisedJan 2021 · 39 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Benjamin J. ZeskindExecutive Officer, Director
Robert CarpenterDirector
Joseph KekstDirector
Andrew PhillipsDirector

Offering amount: $62M
Amount sold: $37.2M
First sale: Dec 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$20MraisedJan 2020 · 67 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Robert CarpenterDirector
Benjamin J. ZeskindExecutive Officer, Director
Joseph KekstDirector

Offering amount: $20M
Amount sold: $20M
First sale: Jan 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Bioworld83 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Immuneering for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Immuneering do?: Immuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Who founded Immuneering?: Immuneering was founded by Benjamin J. Zeskind.
How much funding has Immuneering raised?: Immuneering has disclosed $82.2M raised across 3 rounds.
Where is Immuneering headquartered?: Immuneering is headquartered in Cambridge, US.